Shares of biotechnology company Bionomics experienced a significant surge in early trading on Thursday following the announcement of successful results from their Phase 2b study of their lead drug candidate for post-traumatic stress disorder (PTSD). Promising Results and Market Reaction The Australia-based company's shares soared almost four-fold to $3.89 as investors reacted … [Read more...] about Bionomics Reports Successful Study of Lead Drug Candidate in PTSD
Footer
